Share on PinterestAccording to the latest research, plant-based diets may help prevent a range of chronic conditions, including diabetes. Image credit: Monica Bertolazzi/Getty ImagesResearch shows there are various benefits associated...

(MedPage Today) -- Planned early-term birth based on risk stratification for preeclampsia reduced the incidence of the complication at term compared with usual care, the randomized PREVENT-PE trial showed. Among...

(MedPage Today) -- Members of the Medicare Payment Advisory Commission (MedPAC) generally responded favorably Thursday to a draft recommendation to increase reimbursement in 2027 for physicians who treat Medicare patients...

The results of the 2025 Medicine and Pediatric Specialties Match followed the same patterns seen in recent years for both adult and pediatric rheumatology training program fill rates. Medscape Medical...

(MedPage Today) -- Norma, a mother in Manila, noticed her stomach swelling. She thought she was pregnant again. Ong-Pin, a janitor in Hong Kong, turned yellow and lost weight. Hyo-Jin,...

(MedPage Today) -- ATLANTA -- Young children with Dravet syndrome improved dramatically with a novel gene therapy, according to initial results from a phase I/II trial reported here. Among three...

Compared to hypofractionated radiotherapy, SBRT improves short-term but not long-term QoL in patients with inoperable stage I non-small cell lung cancer, new data show. Medscape Medical News Source link :...

(MedPage Today) -- The American College of Cardiology (ACC) officially backed front-of-package (FOP) nutrition labeling as the expected launch of the public health tool by federal officials draws closer. "FOP...

A majority of the panel approved language that curtails and delays the current universal recommendation. Medscape Medical News Source link : https://www.medscape.com/viewarticle/acip-votes-delay-and-shared-decision-making-hep-b-vaccine-2025a1000y6b?src=rss Author : Publish date : 2025-12-05 19:00:00 Copyright...

(MedPage Today) -- Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi). Approval was supported by findings...

GPs are adopting artificial intelligence tools at pace, but the RCGP warns that patchy guidance, weak regulation, and safety concerns are leaving clinicians exposed. Medscape News UK Source link :...

(MedPage Today) -- Knee injury patterns on MRI were significantly different between males and females across age groups, according to a single-center retrospective study. Among over 13,000 routine knee MRI...

(MedPage Today) -- At the American Society of Nephrology Kidney Week meeting, interim results from the phase III ORIGIN 3 trial showed that investigational atacicept led to a 46% reduction...

(MedPage Today) -- At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), a highlight came during the President's Choice Lecture, where former...

(MedPage Today) -- People with diabetes have a heightened risk for sudden cardiac death, a nationwide Danish study affirmed. In an analysis of every single death in the country in...

(MedPage Today) -- In a sharp break from more than three decades of U.S. vaccine policy, a CDC advisory panel voted Friday to stop recommending that every newborn receive a...

Comet 3I/ATLAS is only the third known visitor to our solar system from elsewhereInternational Gemini Observatory/NOIRLab/NSF/AURA/Shadow the Scientist; J. Miller & M. Rodriguez (Intl Gemini Observatory/NSF NOIRLab), T.A. Rector (University...

Liso-cel now has five approved indications, the most of any CD19-targeted CAR T-cell therapy. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fda-okays-car-t-cell-therapy-marginal-zone-lymphoma-2025a1000y5g?src=rss Author : Publish date : 2025-12-05 16:22:00 Copyright for...

Some researchers are concerned that tattooing brings health risksOlga Kolbakova / Alamy Tattoo ink collects in lymph nodes and interferes with the immune system, causing potentially lifelong changes to the...

(MedPage Today) -- Alzheimer's patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years...